Med Dackonline.se och Continental på Land Rover Experience-resa till Island
Kunder hos Dackonline.se och Continental kan se fram emot en mycket speciell tävling: Mellan den 1 och den 30 april 2017 lottar Europas största däckhandel på nätet tillsammans med premiumdäcktillverkaren ut 16 platser till Land Rover Experience-resan till Island. Den 30/8 till den 4/9 2017 gäller sen: bort från vardagen och ut på Islandsäventyret. Den sex dagar långa Experience-resan går genom bergigt högland, floder och lavafält – den ultimata offroad-utmaningen för både människa och bil. Hänförande vilda landskap och naturskådespel, från vulkaniska sjöar via gejsrar och vattenfall till gigantiska glaciärer, väntar på att upptäckas. Resa tur och retur, hotellövernattningar och transport är redan inkluderat för alla deltagare.
Denna Smart News-version använder multimedia. Se den fulla versionen här: http://www.businesswire.com/news/home/20170420006135/sv/
Den sex dagar långa Experience-resan går genom bergigt högland, floder och lavafält (Photo: Business Wire)
Alla som under kampanjtiden köper minst två Continentaldäck hos Dackonline.se kan delta – erbjudandet gäller alla storlekar och profiler. Registrera dig enkelt i samband med betalningen, svara dessutom på en liten fråga, och med lite tur är du där. Kampanjen pågår i totalt 16 europeiska länder, där en vinnare dras i varje land.
Hos Dackonline.se hittar kunder ett stort urval av Continentaldäck. Den renommerade tillverkaren är ett av de ledande märkena i världen och erbjuder premiumprodukter för alla fordonsklasser. Den som fortfarande är i behov av en uppsättning nya däck lagom till våren, hittar hela sortimentet av sommardäck från renommerade tillverkare hos Dackonline.se. Via den praktiska sökfunktionen hittar kunder snabbt och direkt fram till rätt produkt.
Mer information om tävlingen finns under http://www.dackonline.se/continental-landrover-experience-tour-2017.html.
Om Dackonline.se
Hos Dackonline.se kan intressenter välja bland mer än 100 däckmärken och över 25 000 däckmodeller; häribland även de aktuella testvinnarna. Däck för personbilar, motorcyklar samt lastbilar, nyttofordon och bussar hör till produktgruppen, liksom kompletta hjul, fälgar och reservdelar samt tillbehör till personbilar. Särskilt praktiskt: De nya däcken levereras snabbt och utan kostnad*** till den adress du önskar. Särskilt bekvämt för köpare hos dackonline.se, är möjligheten att kunna få sina däck sända direkt till en av alla 1.500 monteringspartners utan extra kostnad. Flera av de samarbetande verkstäderna erbjuder även ytterligare tjänster kring däck.
***från två däck
Handla däck online:
www.reifendirekt.de, www.reifendirekt.at, www.reifendirekt.ch och www.123pneus.ch www.autobandenmarkt.nl, www.123pneus.fr, www.mytyres.co.uk, www.gommadiretto.it, www.neumaticos-online.es och i många fler Delticom-nätbutiker.
Däcktester: www.dacktest.com
Information om företaget: www.delti.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Se källversionen på businesswire.com: http://www.businesswire.com/news/home/20170420006135/sv/
Contact information
insignis Agentur für
Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
eller
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom